IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.

The surge is attributed to multiple positive developments. The company's core product, senaparib (brand name: Paishuning), has been included in China's National Medical Insurance Directory, with the pricing taking effect earlier this year, which is expected to drive sustained revenue growth. Additionally, market attention is focused on the company's pipeline candidate IMP32, a global first-in-class dual-payload ADC targeting CEACAM5, due to its differentiated positioning.

The company recently completed its IPO, which was heavily oversubscribed, and is one of only three companies globally with both a commercialized PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.